Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 3, 2021

Selva Therapeutics reports positive data from Covid-19 treatment trial

Selva Therapeutics has reported that the Phase I clinical study of a potential oral Covid-19 treatment, SLV213, met its primary objective of demonstrating safety and tolerability.

Selva Therapeutics has reported that the Phase I clinical study of a potential oral Covid-19 treatment, SLV213, met its primary objective of demonstrating safety and tolerability.

A small molecule drug candidate, SLV213 inhibits cathepsin L, a human cysteine protease found in lung and other cells, to block viral entry.

The drug candidate was developed based on research from UC San Diego, which exclusively licensed it to the company.

It potentially has broad antiviral activity against coronaviruses, Ebola viruses and paramyxoviruses, including Nipah virus.

The randomised, placebo-controlled, double-blinded study was conducted in healthy participants.

Data showed that no dose-limiting toxicity was reported in all dose groups tested, hinting at SLV213 being safe for further clinical development.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

According to pharmacokinetic profiles, a dose-dependent increase in SLV213 plasma levels and compatibility with twice-daily dosing was observed.

The company intends to advance SLV213 into a Phase II study in non-hospitalised Covid-19 patients.

Furthermore, Phase I data showed that that SLV213, when administered orally, achieves plasma levels expected to be efficacious based on primate studies.

Selva Therapeutics chief medical officer Ken Krantz said: “We successfully completed our Phase I study with no dose-limiting toxicity.

“This positive outcome, which is further supported by our in vitro and in vivo data that demonstrate the activity of SLV213 as a potent antiviral therapeutic, allows Selva to move forward with testing SLV213 in a Phase II study in early Covid-19 patients.”

Preclinical studies in nonhuman primates (NHPs) in both prophylactic and therapeutic settings demonstrated that SLV213 protected against lung damage infected with SARS-CoV-2, compared to untreated controls.

NHPs treated with SLV213 had normal lung weights in both settings at approximately 0.5% of total body weight, while the lung weights of control animals increased up to two-fold.

The company noted that the increased lung weight indicated severe inflammation and oedema.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU